In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kos/Biovail: How a Mid-Cap Can Win in Primary Care

Executive Summary

In May 2005 Kos Pharmaceuticals took over three of Biovail Corp's hypertension drugs plus most of its associated sales force, paying just 1.4 times 2004 sales-or roughly a fifth of what Biovail had paid for the same products less than five years ago. The deal draws attention to why the two mid-cap companies--similarly sized, and, until recently, with a similar business model--have fared so differently in primary care.
Advertisement

Related Content

NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
Shire/TKT: The Price of Diversification
Shire/TKT: The Price of Diversification
Pliva: Two Steps Forward, One Step Back?
Pliva: Two Steps Forward, One Step Back?
Torcetrapib: Biomarker for the Big Pharma Business Model
Can an Overthrown King Help Mylan?
Can an Overthrown King Help Mylan?
Kos: Right-Sizing Expectations
Kos: Right-Sizing Expectations

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel